#### **Biomedical Research as an Open Digital** Enterprise Philip E. Bourne Ph.D.

NSTITUTES

OF

ATIONAL

**Associate Director for Data Science** National Institutes of Health http://www.slideshare.net/pebourne



HEALTH

#### A View from the Funding Agencies









"It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the season of Light, it was the season of Darkness, it was the spring of hope, it was the winter of despair ..."





#### A Tale of Two Numbers





Growth of Biological Databases





Source Michael Bell http://homepages.cs.ncl.ac.uk/m.j.bell1/blog/?p=830

We (the NIH) Are Working On, But As Yet Do Not Have Good Answers To:

1. Today, how much are we actually spending on data and software related activities?

2. How much should we be spending to achieve the maximum benefit to biomedical science relative to what we spend in other areas?



There are other drivers of change out there besides economics and an increasing emphasis on data and analytics








INTAN INFLUENCE Shift expertise to track mutations where they emerge p.534 EARTH SYSTEMS Past climates give valuable clues to future lo warming 1,527 G

ure lost letter tracked using Google **µ.540** 

S, GOOH MET SON IPUS



Many landmark findings in preclinical oncology research are not reproducible, in part because of inadequate cell lines and animal models.

## Raise standards for preclinical cancer research

C. Glenn Begley and Lee M. Ellis propose how methods, publications and incentives must change if patients are to benefit.

Efforts over the past decade to characterize the genetic alterations in human cancers have led to a better understanding of molecular drivers of this complex set of diseases. Although we in the trials in oncology have the highest failure rate compared with other therapeutic areas. Given the high unmet need in oncology, it is understandable that barriers to clinical development may be lower than for other investigators must reassess their approach translating discovery research into grea clinical success and impact. Many factors are responsible for the h failure rate, notwithstanding the inh

INTUNEY Wybie Vale

hormone 1.542

and an elusive stress

## 47/53 "landmark" publications could not be replicated



#### Must try harder

Too many sloppy mistakes are creeping into scientific papers. Lab heads at the data - and at themselves.

## **Error prone**

Biologists must realize the pitfalls of wor massive amounts of data.

#### If a job is worth doing, it is worth doing twice

Researchers and funding agencies need to put a premium on ensuring that results are reproducible, argues Jonathan F. Russell.

#### The case for open computer programs

Six red flags for suspect work

C. Glenn Begley explains how to recognize the preclinical papers in which the data won't stand up.

# Know when your numbers are significant

[Carole Goble]

#### Reproducibility

 Most of the 27 Institutes and Centers of the NIH are currently reviewing the ability to reproduce research they are funding

 The NIH recently convened a meeting with publishers to discuss the issue – a set of guiding principles arose






#### Reproducibility – More is in the Works

- Much of the research life cycle is now digital encourage the reliability, accessibility, findability, usability of data, methods, narrative, publications etc.
- How?
  - Data sharing plans
  - Standards frameworks
  - Data and software catalogs
  - PubMedCentral
  - **?** The Commons PMC for the complete lifecycle
  - **?** Machine readable data sharing plans
  - **?** Small funding to communities
  - Support for training and best practices in eScholarship





#### **Growth as Another Driver**



From: The Second Machine Age: Work, Progress, and Prosperity in a Time of Brilliant Technologies by Erik Brynjolfsson & Andrew McAfee Evidence:

- Google car
- 3D printers
- Waze
- Robotics









To Summarize Thus Far ...

A time of great (unprecedented?) scientific development but limited funding

# A time of upheaval in the way we do science






#### From a funders perspective...

A time to squeeze every cent/penny to maximize the amount of research that can be done

A time when top down approaches meet bottom up approaches







## **Top Down vs Bottom Up**

Top Down

- Regulations e.g. US: Common Rule, FISMA, HIPPA
- Data sharing policies
  - OSTP
  - GWAS
  - Genome data
  - Clinical trials
- Digital enablement
- Moves towards reproducibility

Bottom Up

- Communities emerge and crowd source
  - Collaboration
  - Data shared
  - Open source software
  - Common principles
  - Standards



#### And Considering This Audience...





It was the age when software developers are in the greatest demand for science..

It was the age when the rewards outside academia are greater than the rewards inside

Che New He	ork Eimes			Tech	nolo	gy	
WORLD U.S.	N.Y. / REGION	BUSINESS	TECHNOLOGY	SCIENCE	HEALTH	SPORTS	OPINION
CAMCORDER	S CAMERAS	CELLPHONES	COMPUTERS	HANDHELDS	HOME VIDI	EO MUSIC	PERIPHER
			u- u				
	1		*				





## Optimistically This is a Time of Opportunity



- The time for software developers is here
- The time to derive new business models is here
- The time to foster best software practices is here





#### Okay so what are we doing about it?





#### To start with we are thinking about the complete research lifecycle






#### The Research Life Cycle

#### **IDEAS – HYPOTHESES – EXPERIMENTS – DATA - ANALYSIS - COMPREHENSION - DISSEMINATION**






### Tools and Resources Will Continue To Be Developed







#### Those Elements of the Research Life Cycle Need to Become More Interconnected Around a Common Framework





**IDEAS** – HYPOTHESES – EXPERIMENTS – DATA - ANALYSIS - COMPREHENSION - DISSEMINATION





#### Those Elements of the Research Life Cycle Need to Become More Interconnected Around a Common Framework





What are we proposing as that common framework?







## The Commons Is ...



- A public/private partnership
- An agile development starting with the evaluation of a few pilots
- An example: porting DbGAP to the cloud
- An experiment with new funding strategies





#### What The Commons Is and Is Not

- Is Not:
  - A database
  - Confined to one physical location
  - A new large infrastructure
  - Owned by any one group


Is:

- A conceptual framework
- Analogous to the Internet
- A collaboratory
- A few shared rules
  - All research objects have unique identifiers
  - All research objects have limited provenance



### **Sustainability and Sharing: The Commons**

Commons == Extramural NCBI == Research Object Sandbox == Collaborative Environment




#### What Does the Commons Enable?

- Dropbox like storage
- The opportunity to apply quality metrics
- Bring compute to the data
- A place to collaborate
- A place to discover





#### **One Possible Commons Business Model**



### **Commons Pilots**

#### Define a set of use cases emphasizing:

- Openness of the system
- Support for basic statistical analysis
- Embedding of existing applications
- API support into existing resources
- Evaluate against the use cases
- Review results & business model with NIH leadership
- Design a pilot phase with various groups
- Conduct pilot for 6-12 months
- Evaluate outcomes and determine whether a wider deployment makes sense
- Report to NIH leadership summer 2015



### What Will Software Development Look Like in the Commons?

- Software identifiers make software:
  - Easy to find
  - Easy of use
  - Easy to cite
- Which means:
  - Need a standard citation scheme
  - Publishers must be encouraged to use it
  - The software index should facilitate the above AND
    - Provide metrics for use
    - Ability to provide commentary



#### **Minimal Software Specification**

- Title

- Version
- License
- Links to source
- Human readable synopsis
- Author names, affiliations
- Ontological terms describing software
- Dependencies
- Acknowledgements
- Publications





## Examples of Folks We Want to Engage

- Other funding agencies national and international
- Open Science Framework <u>https://osf.io/</u>
- Evernote <u>https://evernote.com/</u>
- Simtk <u>https://simtk.org/xml/index.xml</u>
- MyExperiment <u>http://www.myexperiment.org/</u>
- Galaxy <u>http://galaxyproject.org/</u>
- Lab notebook systems
- Other systems used already by NIH



# Putting it all together in a coherent strategy....






#### Associate Director for Data Science

Scientific Data Council

**External Advisory Board** 

#### Programmatic Theme



The Biomedical Research Digital Enterprise

#### **BD2K – Commons Users**

- Centers of Excellence in Data Science (Awards 9/14)
- Data Discovery Index Consortium (Award 9/14)
- Training grants awarded (Awards 9/14)
- Software development (Awards 15)
- Standards framework (Awards 15)
- Software index consortium (Award 15)



Awards next year ~\$100M



#### **Mission Statement**

To foster an <u>ecosystem</u> that enables biomedical research to be conducted as a <u>digital enterprise</u> that *enhances health, lengthens life and reduces illness and disability* 





#### Some Acknowledgements

- Eric Green & Mark Guyer (NHGRI)
- Jennie Larkin (NHLBI)
- Leigh Finnegan (NHGRI)
- Vivien Bonazzi (NHGRI)
- Michelle Dunn (NCI)
- Mike Huerta (NLM)
- David Lipman (NLM)
- Jim Ostell (NLM)

NIH

- Andrea Norris (CIT)
- Peter Lyster (NIGMS)
- All the over 100 folks on the BD2K team

